The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 03, 2018

Filed:

Oct. 09, 2013
Applicants:

The Brigham and Women's Hospital, Inc., Boston, MA (US);

Massachusetts Institute of Technology, Cambridge, MA (US);

Inventors:

Pedro M. Valencia, Cambridge, MA (US);

Eric M. Pridgen, Boston, MA (US);

Suresh Gadde, Brookline, MA (US);

Rohit Karnik, Cambridge, MA (US);

Robert S. Langer, Newton, MA (US);

Stephen J. Lippard, Cambridge, MA (US);

Omid C. Farokhzad, Waban, MA (US);

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/48 (2006.01); A61K 45/06 (2006.01); A61K 31/555 (2006.01); A61K 33/24 (2006.01); A61K 9/14 (2006.01); A61K 9/51 (2006.01); A61K 31/4745 (2006.01); A61K 47/34 (2017.01); A61K 47/59 (2017.01); A61K 47/68 (2017.01); A61K 47/69 (2017.01); B82Y 5/00 (2011.01);
U.S. Cl.
CPC ...
A61K 47/482 (2013.01); A61K 9/14 (2013.01); A61K 9/51 (2013.01); A61K 9/5146 (2013.01); A61K 31/4745 (2013.01); A61K 31/555 (2013.01); A61K 33/24 (2013.01); A61K 45/06 (2013.01); A61K 47/34 (2013.01); A61K 47/593 (2017.08); A61K 47/6869 (2017.08); A61K 47/6937 (2017.08); A61K 9/5153 (2013.01); B82Y 5/00 (2013.01);
Abstract

Provided herein are compositions that contain a nanoparticle containing a plurality of polymers, wherein at least a fraction of the polymers comprise a hydrophobic polymer, a topoisomerase inhibitor, and a Pt-containing chemotherapeutic agent, where the polymers self-assemble in an aqueous liquid to form the nanoparticle, and where the Pt-containing chemotherapeutic agent and the topoisomerase inhibitor are present within the hydrophobic core of the nanoparticle in a ratio of between about 24:1 to about 1:24. Also provided are methods of reducing the proliferation of a cancer cell and methods of treating cancer in a subject that include the use of these compositions. Also provided are methods of making these nanoparticles.


Find Patent Forward Citations

Loading…